Mark Wainberg

Dr Wainberg was a panelist for the Forum’s discussion on Treatment as Prevention.

Mark A. Wainberg is head of AIDS research at the Lady Davis Institute for Medical Research (LDI), Director of the McGill University AIDS Centre located at the LDI, and Professor of Medicine and of Microbiology and Immunology at McGill University in Montreal. He is an internationally recognized scientist in the field of HIV/AIDS, who served as President of the International AIDS Society between 1998 and 2000 with responsibilities that included organizating the XIIIth International Congress on AIDS in Durban, South Africa in 2000. Dr. Wainberg is proud of the role that he played in choosing South Africa as a venue for this congress, which had an important impact on the issue of access to anti-HIV drugs in developing countries.

He is well-known for his initial identification of 3TC as an anti-viral drug, in collaboration with BioChem Pharma Inc, in 1989, as well as for multiple contributions to the field of HIV drug resistance. His laboratory continues to work in the fields of drug resistance and drug development. As well, Dr. Wainberg has turned his attention to novel concepts in the prevention of HIV infection in developing countries, such as vaginal microbicides and pre-exposure prophylaxis. He was Co-Chair of the XVIth International AIDS Conference that took place in Toronto in 2006. Dr. Wainberg is a member of numerous international advisory committees in the field of AIDS. Among other distinctions, he is a fellow of the Royal Society of Canada, an Officer of the Order of Canada, an officer of the Ordre National du Québec, an honorary fellow of the Royal College of Physicians and Surgeons of Canada, and a Chevalier in the Legion d’Honneur of France.